Comparison

Amycretin vs. Liraglutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Amycretin	Liraglutide
Germany	Unapproved	Prescription
United States	Unapproved	Prescription

Full entries

Frequently asked questions

What is the difference between Amycretin and Liraglutide?: Amycretin is classified as "Metabolic", while Liraglutide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Liraglutide?: The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Liraglutide in Germany and the United States?: Germany: Amycretin — Unapproved, Liraglutide — Prescription. United States: Amycretin — Unapproved, Liraglutide — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Liraglutide

Germany

Unapproved

Prescription

United States

Unapproved

Prescription

Frequently asked questions

What is the difference between Amycretin and Liraglutide?

Amycretin is classified as "Metabolic", while Liraglutide is classified as "Metabolic". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Liraglutide?

The highest available evidence level is "Human RCT" for Amycretin and "Human RCT" for Liraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Liraglutide in Germany and the United States?

Germany: Amycretin — Unapproved, Liraglutide — Prescription. United States: Amycretin — Unapproved, Liraglutide — Prescription. These are factual summaries with source and review date on the individual pages.